Company intelligence / Profile preview

Jiangsu Nhwa Pharmaceutical

Xuzhou, Jiangsu, Chinaen.nhwa-group.com ↗

Ownership: Public · 002262
Employees: ~5923
Development stage: Commercial

Overview

Market leader in CNS drugs with commercial products and late-stage partnerships including FDA-approved AUSTEDO® commercialization in China[4][7]. Maintains three GMP production bases producing APIs and formulations[2].

Therapeutic areas: OtherPsychiatryCardiovascularNeurology
Modalities: Small moleculesBiologics (via Teva partnership)
Industry: Biotech

Drug pipeline

17 assets

NH-102

16 more assets in the full pipeline.

Request access →

Partnerships

Teva Pharmaceutical Industries Ltd.:Commercialization of AUSTEDO® in China(2024)Trevena Inc.:Development/commercialization of OLINVYK® in China(2018-)National Academy of Military Medical SciencesIptakalim development

Beyond the preview

Go deeper on Jiangsu Nhwa Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Nhwa Pharmaceutical.

Explore the full profile